Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 6
Managing Luspatercept Therapy: Dosing, Adverse Effects, and Monitoring
Panelists discuss how they approach luspatercept dosing strategies in clinical practice; manage treatment-related adverse events such as fatigue, hypertension, and diarrhea; and monitor labs for signs of relapse, while also considering real-world dose escalation outcomes and the correlation between peripheral blood and bone marrow biopsy mutations in patients with MDS.
Video content above is prompted by the following:
- What is your dosing strategy for luspatercept in your clinical practice?
- Please comment on Patel K, et al. Real-world luspatercept dose escalation and outcomes. EHA 2024 abstract.
- Please describe some potential treatment-related adverse events associated with luspatercept that you’ve observed in your clinical practice.
- How do you manage fatigue, hypertension, and diarrhea?
- What labs do you monitor and recheck for if you are concerned that this patient is relapsing?
- Resource links: DeZern AE, et al. Correlation between PB and BMBx mutations from national MDS study. ASH 2023 abstract.
Related Content:
